NasdaqGS:IONSBiotechs
FDA Priority Review And 2026 Outlook Might Change The Case For Investing In Ionis (IONS)
In late February 2026, Ionis Pharmaceuticals reported full-year 2025 results showing revenue of US$943.71 million and a net loss of US$381.39 million, while also issuing 2026 revenue guidance of US$800 million to US$825 million.
Around the same time, Ionis gained regulatory momentum with the FDA granting Priority Review to olezarsen for severe hypertriglyceridemia and new DAWNZERA Phase 3 data being highlighted at a major allergy conference, underscoring the breadth of its RNA-targeted...